Frequency and distribution of single-nucleotide polymorphisms within mprF in methicillin-resistant Staphylococcus aureus clinical isolates and their role in cross-resistance to daptomycin and host defense antimicrobial peptides

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4930-4937

  Bayer, Arnold S ^a,b   Mishra, Nagendra N ^a,b   Chen, Liang ^c   Kreiswirth, Barry N ^c   Rubio, Aileen ^d   Yang, Soo Jin ^a,e  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d CUBIST PHARMACEUTICALS INC   (United States)

^e Chung Ang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; SYNTHETASE; THROMBIN; THROMBIN INDUCED PLATELET MICROBICIDAL PROTEIN; UNCLASSIFIED DRUG; AMINOACYLTRANSFERASE; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BACTERIAL PROTEIN; METICILLIN; MPRF PROTEIN, STAPHYLOCOCCUS AUREUS;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CARBOXY TERMINAL SEQUENCE; CROSS RESISTANCE; GENE LOCUS; HOST RESISTANCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MODIFICATION; SINGLE NUCLEOTIDE POLYMORPHISM; SURFACE CHARGE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; PENICILLIN RESISTANCE; PROCEDURES; STAPHYLOCOCCAL INFECTIONS;

AMINOACYLTRANSFERASES; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL PROTEINS; DAPTOMYCIN; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; METHICILLIN; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; STAPHYLOCOCCAL INFECTIONS;

EID: 84939825760     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00970-15     Document Type: Article

References (51)

1. Fowler VG, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS, ICE Investigators. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012-3021. http://dx.doi.org/10.1001/jama.293.24.3012.
2. Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, Corey GR, Olaison L, Eykyn S, Hoen B, Abrutyn E, Raoult D, Bayer A, Fowler VG, Jr, International Collaboration on Endocarditis Merged Database Study Group. 2005. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 41:507-514. http://dx.doi.org/10.1086/431979.
3. Ammerlaan HSM, Harbarth S, Buiting AGM, Crook DW, Fitzpatrick F, Hanberger H, Herwaldt LA, van Keulen PHJ, Kluytmans JAJW, Kola A, Kuchenbecker RS, Lingaas E, Meessen N, Morris-Downes MM, Pottinger JM, Rohner P, dos Santos RP, Seifert H, Wisplinghoff H, Ziesing S, Walker AS, Bonten MJM. 2013. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis 56:798-805. http://dx.doi.org/10.1093/cid/cis1006.
4. Rose WE, Rybak MJ, Kaatz GW. 2007. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 60:334-340. http://dx.doi.org/10.1093/jac/dkm170.
5. Schriever CA, Fernandez C, Rodvold KA, Danziger LH. 2005. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 62:1145-1158.
6. Tally FP, DeBruin MF. 2000. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 46:523-526. http://dx.doi.org/10.1093/jac/46.4.523.
7. Arias CA, Torres HA, Singh KV, Panesso D, Moore J, Wanger A, Murray BE. 2007. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 45:1343-1346. http://dx.doi.org/10.1086/522656.
8. Bayer AS, Schneider T, Sahl H-G. 2013. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 1277:139-158. http://dx.doi.org/10.1111/j.1749-6632.2012.06819.x.
9. Boucher HW, Sakoulas G. 2007. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 45:601-608. http://dx.doi.org/10.1086/520655.
10. Humphries RM, Pollett S, Sakoulas G. 2013. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 26:759-780. http://dx.doi.org/10.1128/CMR.00030-13.
11. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, Schrenzel J, Xiong YQ, Bayer AS. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 52:269-278. http://dx.doi.org/10.1128/AAC.00719-07.
12. Mariani PG, Sader HS, Jones RN. 2006. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother 58:481-483. http://dx.doi.org/10.1093/jac/dkl256.
13. Bayer AS, Mishra NN, Sakoulas G, Nonejuie P, Nast CC, Pogliano J, Chen K-T, Ellison SN, Yeaman MR, Yang S-J. 2014. Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides. Antimicrob Agents Chemother 58:7462-7467. http://dx.doi.org/10.1128/AAC.03422-14.
14. Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 50:2137-2145. http://dx.doi.org/10.1128/AAC.00039-06.
15. Julian K, Kosowska-Shick K, Whitener C, Roos M, Labischinski H, Rubio A, Parent L, Ednie L, Koeth L, Bogdanovich T, Appelbaum PC. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob Agents Chemother 51:3445-3448. http://dx.doi.org/10.1128/AAC.00559-07.
16. Mishra NN, Yang S-J, Chen L, Muller C, Saleh-Mghir A, Kuhn S, Peschel A, Yeaman MR, Nast CC, Kreiswirth BN, Crémieux A-C, Bayer AS. 2013. Emergence of daptomycin resistance in daptomycin-naive rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS One 8:e71151. http://dx.doi.org/10.1371/journal.pone.0071151.
17. Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC, Jr, Eliopoulos GM. 2007. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother 51:2223-2225. http://dx.doi.org/10.1128/AAC.00202-07.
18. Staubitz P, Neumann H, Schneider T, Wiedemann I, Peschel A. 2004. MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance. FEMS Microbiol Lett 231:67. http://dx.doi.org/10.1016/S0378-1097(03)00921-2.
19. Ernst C, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, Bayer AS, Kraus D, Peschel A. 2009. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog 5:e1000660.
20. Weidenmaier C, Peschel A, Kempf VAJ, Lucindo N, Yeaman MR, Bayer AS. 2005. DltABCD- and MprF-mediated cell envelope modifications of Staphylococcus aureus confer resistance to platelet microbicidal proteins and contribute to virulence in a rabbit endocarditis model. Infect Immun 73:8033-8038. http://dx.doi.org/10.1128/IAI.73.12.8033-8038.2005.
21. Yang SJ, Xiong YQ, Dunman PM, Schrenzel J, Francois P, Peschel A, Bayer AS. 2009. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus. Antimicrob Agents Chemother 53:2636-2637. http://dx.doi.org/10.1128/AAC.01415-08.
22. Yang S-J, Mishra NN, Rubio A, Bayer AS. 2013. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob Agents Chemother 57:5658-5664. http://dx.doi.org/10.1128/AAC.01184-13.
23. Yang S-J, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. 2010. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother 54:3079-3085. http://dx.doi.org/10.1128/AAC.00122-10.
24. Bertsche U, Yang S-J, Kuehner D, Wanner S, Mishra NN, Roth T, Nega M, Schneider A, Mayer C, Grau T, Bayer AS, Weidenmaier C. 2013. Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. PLoS One 8:e67398. http://dx.doi.org/10.1371/journal.pone.0067398.
25. Mishra NN, Bayer AS, Weidenmaier C, Grau T, Wanner S, Stefani S, Cafiso V, Bertuccio T, Yeaman MR, Nast CC, Yang S-J. 2014. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One 9:e107426. http://dx.doi.org/10.1371/journal.pone.0107426.
26. Rubio A, Conrad M, Haselbeck RJ, Kedar GC, Brown-Driver V, Finn J, Silverman JA. 2011. Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus. Antimicrob Agents Chemother 55:364-367. http://dx.doi.org/10.1128/AAC.00429-10.
27. Bayer AS, Prasad R, Chandra J, Koul A, Smriti M, Varma A, Skurray RA, Firth N, Brown MH, Koo S-P, Yeaman MR. 2000. In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. Infect Immun 68:3548-3553. http://dx.doi.org/10.1128/IAI.68.6.3548-3553.2000.
28. Dhawan VK, Bayer AS, Yeaman MR. 1998. In vitro resistance to thrombin-induced platelet microbicidal protein is associated with enhanced progression and hematogenous dissemination in experimental Staphylococcus aureus infective endocarditis. Infect Immun 66:3476-3479.
29. Dhawan VK, Bayer AS, Yeaman MR. 2000. Thrombin-induced platelet microbicidal protein susceptibility phenotype influences the outcome of oxacillin prophylaxis and therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 44:3206-3209. http://dx.doi.org/10.1128/AAC.44.11.3206-3209.2000.
30. Yeaman MR, Bayer AS, Koo S-P, Foss W, Sullam PM. 1998. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J Clin Invest 101:178-187. http://dx.doi.org/10.1172/JCI562.
31. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, Bayer AS. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53:2312-2318. http://dx.doi.org/10.1128/AAC.01682-08.
32. Yang SJ, Kreiswirth BN, Sakoulas G, Yeaman MR, Xiong YQ, Sawa A, Bayer AS. 2009. Enhanced expression of dltABCD is associated with development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 200:1916-1920. http://dx.doi.org/10.1086/648473.
33. Yeaman MR, Puentes SM, Norman DC, Bayer AS. 1992. Partial characterization and staphylocidal activity of thrombin-induced platelet microbicidal protein. Infect Immun 60:1202-1209.
34. Yeaman MR, Sullam PM, Dazin PF, Bayer AS. 1994. Platelet microbicidal protein alone and in combination with antibiotics reduces Staphylococcus aureus adherence to platelets in vitro. Infect Immun 62:3416-3423.
35. Xiong YQ, Mukhopadhyay K, Yeaman MR, Adler-Moore J, Bayer AS. 2005. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob Agents Chemother 49:3114-3121. http://dx.doi.org/10.1128/AAC.49.8.3114-3121.2005.
36. Meehl M, Herbert S, Götz F, Cheung A. 2007. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 51:2679-2689. http://dx.doi.org/10.1128/AAC.00209-07.
37. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Götz F. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 274:8405-8410. http://dx.doi.org/10.1074/jbc.274.13.8405.
38. Oku Y, Kurokawa K, Ichihashi N, Sekimizu K. 2004. Characterization of the Staphylococcus aureus mprF gene, involved in lysinylation of phosphatidylglycerol. Microbiology 150:45-51. http://dx.doi.org/10.1099/mic.0.26706-0.
39. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, Kalbacher H, Nieuwenhuizen WF, Jung G, Tarkowski A, van Kessel KPM, van Strijp JAG. 2001. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J Exp Med 193:1067-1076. http://dx.doi.org/10.1084/jem.193.9.1067.
40. Mukhopadhyay K, Whitmire W, Xiong YQ, Molden J, Jones T, Peschel A, Staubitz P, Adler-Moore J, McNamara PJ, Proctor RA, Yeaman MR, Bayer AS. 2007. In vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry. Microbiology 153:1187-1197. http://dx.doi.org/10.1099/mic.0.2006/003111-0.
41. Cheung AL, Bayer AS, Yeaman MR, Xiong YQ, Waring AJ, Memmi G, Donegan N, Chaili S, Yang S-J. 2014. Site-specific mutation of the sensor kinase GraS in Staphylococcus aureus alters the adaptive response to distinct cationic antimicrobial peptides. Infect Immun 82:5336-5345. http://dx.doi.org/10.1128/IAI.02480-14.
42. Mishra NN, McKinnell J, Yeaman MR, Rubio A, Nast CC, Chen L, Kreiswirth BN, Bayer AS. 2011. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 55:4012-4018. http://dx.doi.org/10.1128/AAC.00223-11.
43. Cui L, Tominaga E, Neoh HM, Hiramatsu K. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50:1079-1082. http://dx.doi.org/10.1128/AAC.50.3.1079-1082.2006.
44. Ernst CM, Kuhn S, Slavetinsky CJ, Krismer B, Heilbronner S, Gekeler C, Kraus D, Wagner S, Peschel A. 2015. The lipid-modifying multiple peptide resistance factor is an oligomer consisting of distinct interacting synthase and flippase subunits. mBio 6(1):e02340-14. http://dx.doi.org/10.1128/mBio.02340-14.
45. Yang S-J, Bayer AS, Mishra NN, Meehl M, Ledala N, Yeaman MR, Xiong YQ, Cheung AL. 2012. The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to selected cationic antimicrobial peptides. Infect Immun 80:74-81. http://dx.doi.org/10.1128/IAI.05669-11.
46. Bertsche U, Weidenmaier C, Kuehner D, Yang S-J, Baur S, Wanner S, Francois P, Schrenzel J, Yeaman MR, Bayer AS. 2011. Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation. Antimicrob Agents Chemother 55:3922-3928. http://dx.doi.org/10.1128/AAC.01226-10.
47. Mishra NN, Liu GY, Yeaman MR, Nast CC, Proctor RA, McKinnell J, Bayer AS. 2011. Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides. Antimicrob Agents Chemother 55:526-531. http://dx.doi.org/10.1128/AAC.00680-10.
48. Patton TG, Yang S-J, Bayles KW. 2006. The role of proton motive force in expression of the Staphylococcus aureus cid and lrg operons. Mol Microbiol 59:1395-1404. http://dx.doi.org/10.1111/j.1365-2958.2006.05034.x.
49. Li M, Cha DJ, Lai Y, Villaruz AE, Sturdevant DE, Otto M. 2007. The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol Microbiol 66:1136-1147. http://dx.doi.org/10.1111/j.1365-2958.2007.05986.x.
50. Mishra NN, Bayer AS. 2013. Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57:1082-1085. http://dx.doi.org/10.1128/AAC.02182-12.
51. Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G. 2012. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis 206:1160-1167. http://dx.doi.org/10.1093/infdis/jis482.